Draft:Optellum
| Submission declined on 17 June 2025 by Cinder painter (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Company type | Private |
|---|---|
| Industry | Healthcare technology |
| Founded | 2016 |
Key people | Michael Brady (Co-founder), Václav Potěšil (Co-founder), Johnathan Watkins (CEO) |
| Website | optellum.com |
Optellum is a British medtech company founded in 2016 and headquartered at the Oxford Centre for Innovation in Oxford, UK, with a U.S. office in Houston, Texas.[1][2] It specializes in developing AI-powered clinical decision support tools for early lung cancer detection, diagnosis, and nodule management.
History
[edit]Optellum was co‑founded in 2016 by Václav Potěšil, Lyndsey Pickup, Timor Kadir, Jérôme Declerck, and Professor Sir Michael Brady. The founders met at the University of Oxford’s computer vision laboratory, raising seed and grant funding, including a €0.5 million EIT Health grant in 2016.[1][3]
In September 2022, the company raised a US $14 million Series A funding round led by Mercia and Intuitive Ventures.[4]
Products and Technology
[edit]Optellum’s primary solution, the Virtual Nodule Clinic (VNC), integrates machine learning‑derived Lung Cancer Prediction (LCP) scores with natural language processing to identify, score, and track the risk of lung nodules from CT scans and radiology reports. The software assists pulmonologists and radiologists in nodule management and supports clinical decision-making.[1]
In March 2021, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to VNC, marking it as the first FDA‑cleared AI‑based clinical decision support software for early lung cancer diagnosis.[5][6]. Subsequently, it received CE‑MDR certification in the EU and UKCA marking in the UK in 2022, becoming the first and only medtech company to achieve this triple regulatory clearance across these regions.[7]
Awards and Recognition
[edit]Optellum has received backing from public bodies like Innovate UK,[8] NHS England’s AI Lab,[9] and EIT Health.[3] Its DOLCE study — a multi‑centre clinical validation across ten NHS hospitals — received funding through the £140 million NHS AI Lab award.[10] In June 2022, the U.S. Centers for Medicare & Medicaid Services (CMS) assigned a New Technology APC payment classification to VNC’s LCP score, supporting reimbursement in the U.S.[11]
References
[edit]- ^ a b c "Community Stories – Optellum's AI‑Powered Journey with EIT Health" (PDF).
- ^ "Houston's Rapidly Growing Healthtech Startups Sourcing Executive Talent From Healthcare and Beyond". 7 December 2021.
- ^ a b "EIT Health supported Optellum in AI world-first".
- ^ "Intuitive joins $14M funding for lung cancer AI developer Optellum".
- ^ "FDA 510(k) summary for K202300, decision dated March 5 2021" (PDF).
- ^ "FDA database entry confirming classification and clearance date".
- ^ "CE‑MDR and UKCA certification statement".
- ^ "The Integration and Analysis of Data using Artificial Intelligence to Improve Patient Outcomes with Thoracic Diseases (DART)".
- ^ "Oxford spin-out Optellum attains CE marking for its early lung cancer diagnosis AI technology".
- ^ "AI could help doctors detect lung cancer at earlier stage". 15 March 2024.
- ^ "July 2022 Update of the Hospital Outpatient Prospective Payment System (OPPS)" (PDF).